Most people know to keep an eye on their LDL (“bad”) cholesterol. But there is another lipid particle quietly elevating the cardiovascular risk of roughly one in five people — and the majority have never been tested for it. It is called lipoprotein(a), or Lp(a), and new research is reinforcing just how significant a threat persistently elevated levels can pose to the heart and brain.
What Is Lipoprotein(a)?
Lipoprotein(a) is a type of low-density lipoprotein (LDL) particle with an extra protein — apolipoprotein(a) — chemically bonded to its surface. This structural difference makes Lp(a) particularly damaging. While standard LDL ferries cholesterol through the bloodstream, the apolipoprotein(a) component makes Lp(a) stickier and more prone to triggering inflammation in artery walls. It also interferes with the body’s natural clot-dissolving process, raising the risk of arterial plaques and blood clots simultaneously.
Lp(a) levels are measured either in milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L). Researchers generally consider levels above 50 mg/dL (or 125 nmol/L) to be elevated. At this threshold and beyond, studies indicate a substantially higher lifetime risk of coronary heart disease, heart attack, stroke, and aortic valve stenosis — a condition in which the heart’s main outflow valve gradually narrows.
Why Most People Have Never Heard of It
Unlike LDL cholesterol — a household name thanks to decades of public health campaigns — Lp(a) has long been absent from standard lipid panels. A routine blood test at your annual physical almost certainly does not measure it. This has left millions of people unaware they carry a significant genetic risk factor for heart disease.
Recent cardiovascular research is drawing renewed attention to this gap. A study published in JAMA Cardiology and other peer-reviewed journals found that even patients who had already undergone statin treatment and achieved optimal LDL targets continued to experience major cardiovascular events at substantially higher rates if their Lp(a) remained elevated. In other words, controlling LDL alone does not neutralize the risk conferred by high Lp(a).
“Lp(a) is increasingly recognized as an independent and persistent cardiovascular risk factor that remains elevated regardless of lifestyle modification,” noted one large-scale cardiovascular analysis drawing on data from biobank cohorts across Europe and North America.
A Largely Inherited Risk
One of the defining characteristics of Lp(a) is that it is primarily determined by genetics. Approximately 70–90% of your Lp(a) level is inherited, encoded by the LPA gene. This means that unlike LDL — which responds meaningfully to diet, exercise, and medication — Lp(a) levels are largely fixed from birth and do not change much with lifestyle interventions.
Certain ethnic groups carry higher average Lp(a) concentrations. Research suggests people of South Asian and Black African ancestry tend to have higher Lp(a) levels on average compared to people of European ancestry, though elevated Lp(a) affects individuals across all populations. If a first-degree relative has been diagnosed with premature heart disease (before age 55 in men or 65 in women), asking about Lp(a) testing is especially worthwhile.
Who Should Get Tested?
Major cardiovascular organizations, including the European Society of Cardiology (ESC) and the American Heart Association (AHA), recommend at least one Lp(a) measurement in every adult’s lifetime as part of cardiovascular risk assessment — particularly for individuals with:
- A family history of early heart disease or heart attack
- Familial hypercholesterolemia (an inherited form of high cholesterol)
- Personal history of cardiovascular events despite well-managed LDL
- Aortic valve stenosis without a clear cause
- Recurrent pregnancy complications linked to placental insufficiency
Because Lp(a) levels are stable over a lifetime in most people, a single test is generally sufficient to establish baseline risk. The test requires a standard blood draw and is increasingly available through primary care providers, though insurance coverage varies.
Current Treatment Options
This is where managing Lp(a) becomes challenging: no currently approved medication is specifically designed to target it. Common interventions have limited effect:
- Statins: Effective at lowering LDL, but studies indicate they have minimal impact on Lp(a) and may slightly increase levels in some individuals.
- PCSK9 inhibitors (such as evolocumab and alirocumab): These injectable medications primarily lower LDL but research suggests they can reduce Lp(a) by 20–30% as a secondary effect — meaningful, but often not enough to bring very high levels into a safe range.
- Niacin (vitamin B3): Can lower Lp(a) by roughly 20–30%, but large clinical trials failed to show a meaningful reduction in cardiovascular events, and the side-effect profile limits its use.
The more exciting developments are happening in the clinical trial pipeline. A class of RNA-targeting drugs — specifically antisense oligonucleotides and small interfering RNA (siRNA) therapies — are showing dramatic results in reducing Lp(a). Pelacarsen, an antisense therapy by Novartis, and olpasiran, an siRNA therapy by Amgen, have both demonstrated reductions of 80–95% in Lp(a) levels in Phase 2 trials. Large Phase 3 outcome trials are currently underway, and the cardiovascular research community is watching closely.
What You Can Do Now
If you discover you have elevated Lp(a), a healthcare provider may recommend a multi-pronged approach to managing overall cardiovascular risk:
- Aggressively optimize other risk factors: Since Lp(a) itself is hard to lower, bringing LDL, blood pressure, blood sugar, and inflammation down to optimal levels becomes even more important.
- Anti-inflammatory diet: Research suggests a Mediterranean-style diet rich in fruits, vegetables, olive oil, legumes, and fatty fish can reduce overall cardiovascular inflammation, potentially offsetting some of the vascular damage associated with high Lp(a).
- Regular aerobic exercise: While it does not lower Lp(a) directly, studies indicate consistent moderate-to-vigorous exercise improves arterial health, reduces inflammation, and lowers overall cardiovascular mortality.
- Quit smoking: Smoking compounds arterial injury and greatly amplifies the risk already present with elevated Lp(a).
- Consider low-dose aspirin carefully: Given Lp(a)’s role in promoting blood clots, some cardiologists discuss antiplatelet therapy — but this is a highly individualized decision that must be made with a physician.
If you are concerned about your cardiovascular risk and have never had an Lp(a) test, speaking with your healthcare provider about adding it to your next blood panel is a reasonable first step. Early knowledge allows for earlier risk management — and with promising therapies in the pipeline, that knowledge may soon be directly actionable in new ways.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.